Association between simulated ketamine exposures and oxygen saturations in children.

Dr. Daniel Gonzalez is an Associate Professor in the Division of Clinical Pharmacology of the Department of Medicine at the Duke University School of Medicine, and a member of the Duke Clinical Research Institute. Gonzalez received his PharmD and PhD from the University of Florida College of Pharmacy in 2008 and 2012, respectively. He then completed a postdoctoral fellowship through the UNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training Program. Following completion of his post-doctoral training, Gonzalez served as a faculty member at the UNC Eshelman School of Pharmacy between 2014 and 2023 and moved to Duke University in 2023. 

Gonzalez’s experiences have afforded a highly collaborative and multidisciplinary research program focused on advancing public health by promoting the safe, effective, and individualized use of drugs, with an emphasis on pediatric populations. His research interests include clinical pharmacology and applying mathematical modeling and simulation techniques to characterize the pharmacokinetics and pharmacodynamics of drugs, guide drug dosage selection, and improve drug safety. Gonzalez’s research program is funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and he has published >110 peer-reviewed publications and >40 abstracts. He has been the major advisor for 8 PhD students (4 completed, 4 in training) and 15 postdoctoral fellows.

I am an Assistant Professor of Pediatrics and a Pediatric Critical Care Physician at Duke University School of Medicine, and I am also affiliated with the Duke Clinical Research Institute (DCRI). My research focuses on advancing pediatric healthcare through the integration of biostatistics, clinical research informatics, and data science. I have significant experience managing large datasets, including the Pediatrix Medical Group Clinical Data Warehouse and the NICHD-funded Pediatric Trials Network, which have provided vital insights into disease patterns and pediatric drug labeling. I contribute analytical support to various pediatric research initiatives. My efforts extend to exploring automation of data integration in clinical trials, enhancing research infrastructure, and leading critical trials and registries to improve pediatric health outcomes. I am enthusiastic about applying my expertise in biostatistics, database management, and predictive analytics to future projects.

Pediatric and adult clinical pharmacology and clinical trials.